Core Insights - After-hours trading in the U.S. saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of catalyst-driven moves and sentiment-based rebounds following the Fed's rate cut Group 1: Notable After-Hours Gainers - Agape ATP Corp. (ATPC) surged 29.41% after hours to $0.088, despite no specific news, reflecting a broader risk-on sentiment in micro-cap stocks [1] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) rose 12.76% after hours to $11.57, driven by anticipation of a key clinical update on its Phase 1a study of CRB-913 [2] - Anebulo Pharmaceuticals, Inc. (ANEB) increased 8.37% after hours to $2.33, aligning with the overall positive sentiment in small-cap biotech [3] - Cue Biopharma, Inc. (CUE) gained 13.12% after hours to $0.54, with no new developments, indicating a macro-driven recovery in biotech [4] - Curis, Inc. (CRIS) saw a 7.68% increase after hours to $1.3999, following positive clinical data presented at the ASH Annual Meeting [5] - Skye Bioscience, Inc. (SKYE) rose 7.02% after hours to $1.22, benefiting from the overall biotech market lift [6] - Cerus Corporation (CERS) increased 3.17% after hours to $1.95, continuing its upward trend after announcing a purchasing agreement with Blood Centers of America [7]

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, nimacimab [1][3]. Group 1: Allegations - The complaint alleges that during the class period from November 4, 2024, to October 3, 2025, the defendants issued materially false and misleading statements regarding nimacimab's effectiveness [3]. - It is claimed that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to inflated public statements by the defendants [3]. Group 2: Shareholder Actions - Shareholders who purchased shares of SKYE during the specified class period are encouraged to register for the class action, with a deadline set for January 16, 2026 [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [5].

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead product candidate, nimacimab, which was claimed to be less effective than represented [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the company overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Skye Bioscience, Inc. is facing legal action from investors following the failure of its clinical trial for nimacimab, which did not meet its primary endpoint for weight loss compared to placebo [4]. Group 1: Legal Action - A lawsuit has been filed against Skye Bioscience, Inc. by an investor alleging violations of securities laws, claiming that the company made false or misleading statements regarding the effectiveness of nimacimab [4]. - Investors who purchased over $100,000 in Skye Bioscience shares between November 4, 2024, and October 3, 2025, have a deadline of January 16, 2026, to take action [2]. Group 2: Clinical Trial Details - Skye Bioscience initiated the "CBeyond" clinical trial in August 2024, a 26-week study aimed at assessing nimacimab for obesity treatment, with a primary endpoint of an 8% difference in mean weight loss compared to placebo [3]. - On October 6, 2025, the company announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, and preliminary analysis indicated lower than expected drug exposure [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from November 4, 2024, to October 3, 2025 [2][6]. Group 1: Class Action Details - Investors who purchased Skye securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 16, 2026 [4]. - The lawsuit alleges that Skye's management made materially false and misleading statements regarding the effectiveness and prospects of its product, nimacimab, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [5]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [5].

Core Points - Rosen Law Firm is reminding purchasers of Skye Bioscience, Inc. securities of the January 16, 2026 lead plaintiff deadline for a class action lawsuit [1][2] - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][4] Company Details - The lawsuit alleges that Skye's defendants made materially false and misleading statements regarding the effectiveness of nimacimab, overstating its clinical, regulatory, and commercial prospects [4] - The firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [3]

ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYEDecember 05, 2025 5:34 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 5, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Per ...

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Summary of Skye's Conference Call Company Overview - **Company**: Skye - **Focus**: Development of CB1 antibody and nimacimab for obesity treatment [1][2] Industry Insights - **Cannabinoid System**: The discussion highlighted the role of the cannabinoid system in energy metabolism and fat storage, referencing the historical context of Rimonabant as a proof of concept for weight loss [3][4] - **Market Dynamics**: The current market is dominated by incretin class drugs, with expectations of price compression affecting GLP-1 medications [44] Core Points and Arguments - **Mechanism of Action**: Skye's nimacimab is designed to be peripherally restricted, avoiding the neuropsychiatric side effects associated with small molecules that penetrate the brain [5][6] - **Preclinical Data**: The company has generated significant preclinical data demonstrating that nimacimab can drive weight loss through a different mechanism than existing drugs, focusing on broader metabolic rewiring [9][10] - **Clinical Findings**: - Phase 2 data indicated that higher doses are necessary for effectiveness, with initial doses being insufficient [14][16] - Combination therapy with tirzepatide showed promising results, with a 30% improvement in weight loss compared to semaglutide [25][26] - The combination therapy maintained weight loss better than semaglutide alone, with only 8-10% weight regain compared to 40% for tirzepatide [12][29] Important but Overlooked Content - **Safety Profile**: The nimacimab has shown a strong safety profile with no neuropsychiatric adverse events reported in clinical trials, which is a significant advantage over previous treatments [6][32] - **Future Development Path**: The company plans to explore higher dosing and combination therapies, aiming for a sweet spot around 600 mg for optimal efficacy [49][50] - **Financial Position**: Skye ended the quarter with approximately $35 million in cash, which is expected to fund upcoming studies and operational needs [59] Next Steps - **Ongoing Studies**: The company is focused on the ongoing extension study to gather more data on dosing and efficacy, with results expected in Q1 [59][41] - **Strategic Focus**: Skye aims to leverage its safety data and preclinical findings to justify higher dosing and explore combination therapies in a competitive market [32][45]